

Supplement F. Medications included in each drug category.*

Non-steroidal anti-inflammatory drugs (NSAIDs)	Slow-acting antirheumatic drugs [†] (SAARDs)	Glucocorticoids (GC)	Tumor necrosis factor inhibitors (TNFi)	Biologicals other than Tumor necrosis factor inhibitors
Aspirin	Apremilast	Methylprednisolone	Adalimumab	Abatacept
Celecoxib	Azathioprine	Prednisone	Certolizumab	Anakinra
Diclofenac	Leflunomide	Triamcinolone	Etanercept	Rituximab
Diflunisal	Methotrexate	Topical formulations	Golimumab	Tocilizumab
Etodolac	Sulfasalazine		Infliximab	Ustekinumab
Fenoprofen	Thalidomide			
Flurbiprofen	Tofacitinib			
Ibuprofen				
Indomethacin	In the setting of SpA:			
Meclofenamic acid	Alendronate			
Meloxicam	Clodronate			
Nabumetone	Etidronate			
Naproxen	Ibandronate			
Oxaprozin	Pamidronate			
Piroxicam	Risedronate			
Salsalate	Tiludronate			
Salicylates	Zoledronate			
Sulindac				
Tolmetin				

* Only medications approved by the U.S. Food and Drug Administration for any indication (not limited to AS) as of 07/19/2014 were considered.

[†]The panel discussed and rejected alternative names for this category.